Dr. Stephen Smith: COVID-19 Patients Died Because Of Bogus Lancet Study That Disparaged Hydroxycholorquine (Video)

(Gateway Pundit) – Infectious Disease Specialist Dr. Stephen Smith joined Laura Ingraham Friday night on The Ingraham Angle.

Dr. Smith has been treating coronavirus patients at the Smith Center for Infectious Diseases and Urban Health in East Orange, New Jersey.

Dr. Smith revealed in April that in his treatment of coronavirus victims he has not seen a single patient under the age of 70 who was not diabetic, pre-diabetic or obese.

Dr. Stephen Smith then pointed out that not a single coronavirus patient under his care who was on the hydroxychloroquine regimen needed to be intubated.

This is outstanding news.

But then two weeks ago The Lancet published a “study” that found hydroxychloroquine was not effective and actually harmful to coronavirus patients.

But this week The Lancet apologized for putting up the study after it was revealed to be a complete fraud.

We wrote about this extensively earlier today.

Notice the red text on the spreadsheet are notes to adjust the data to fit their conclusion.

On Friday night Dr. Stephen Smith told Laura Ingraham that because of this bogus study reported in The Lancet people died.

Dr. Stephen Smith: “I agree. I think people have died over this and I don’t say that lightly at all.”

Via The Ingraham Angle:


Visit the USSA News store!
Click this link for the original source of this article.
Author: JoshKulp

This content is courtesy of, and owned and copyrighted by, https://www.teaparty.org and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu. The owner of this website may be paid to recommend American Bullion. The content of this website, including the positive review of American Bullion, the negative review of its competitors, and any other information may not be independent or neutral.